Back to top
more

Valeritas Holdings, Inc. (VLRX)

(Delayed Data from NSDQ)

$0.34 USD

0.34
2,205,466

+0.03 (9.85%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.34 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Medtronic's All Business Lines Grow Despite Cost Concerns

Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.

Boston Scientific (BSX) Upbeat on Results of EVOLVE Study

Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.

Haemonetics Grows on Strong Plasma, Hemostasis Management

Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.

NuVasive Announces Innovations in Robotics Spine Surgery Line

NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.

GNC Holdings Inks Retail Partnership Deal to Grow in Brazil

We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.

Innovation Aids Genomic Health, Merger Procedure on Track

Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.

Insulet (PODD) Scales 52-Week High: What's Driving the Stock?

Insulet (PODD) has various favorable factors to maintain the current high.

Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates

Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 5.86% and 0.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know

Valeritas Holdings, Inc. (VLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

Sanghamitra Saha headshot

Use Rising P/E Strategy to Buy 5 Winning Stocks

Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

Valeritas Holdings, Inc. (VLRX) Reports Q1 Loss, Tops Revenue Estimates

Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 0.00% and 3.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know

Valeritas Holdings, Inc. (VLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

4 Small-Cap Stocks That Are Set to Explode Higher in 2019

With no near-term respite in sight from the ongoing U.S.-China tariff tension, investors are now shifting their focus to smaller domestic companies.

The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas

The Zacks Analyst Blog Highlights: Chimerix, MacroGenics, Rockwell Medical, TG Therapeutics and Valeritas

Nabaparna Bhattacharya headshot

5 Beaten-Down Medical Product Stocks to Rebound in 2019

As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.